Immucell Appoints New CEO Olivier te Boekhorst

Immucell ( (ICCC) ) has issued an announcement.

ImmuCell Corporation announced on September 29, 2025, the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Mr. te Boekhorst brings extensive experience from his previous roles at ARCHIMED and IDEXX Laboratories, where he led significant growth and innovation in the livestock diagnostics sector. This leadership change is expected to drive the company’s growth, particularly in expanding sales of First Defense® and advancing Re-Tain®. The transition will be supported by the current CEO, Michael F. Brigham, who will remain as a Special Advisor and Board member. The company has also structured stock option awards for Mr. te Boekhorst as part of his employment terms.

The most recent analyst rating on (ICCC) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.

Spark’s Take on ICCC Stock

According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.

The overall stock score reflects Immucell’s mixed financial performance and neutral technical indicators. While there is potential for growth, challenges in profitability and valuation concerns weigh on the score. The absence of a dividend yield and high P/E ratio further impact the valuation negatively.

To see Spark’s full report on ICCC stock, click here.

More about Immucell

ImmuCell Corporation is an animal health company focused on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle. The company offers First Defense®, which provides immediate immunity to newborn calves, and is developing Re-Tain®, a treatment for subclinical mastitis in dairy cows that does not require milk discard or pre-slaughter withdrawal.

Average Trading Volume: 10,632

Technical Sentiment Signal: Buy

Current Market Cap: $55.9M

For a thorough assessment of ICCC stock, go to TipRanks’ Stock Analysis page.